Clinical trials: sargramostim, open to volunteers
Breast Cancer, Metastatic Breast Cancer
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced…
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
- Trial name
- BRIA-ABC (NCT06072612)
- Testing
- SV-BR-1-GM, Cyclophosphamide, Interferon infiltration of the inoculation site
- Where
- 79 sites in United States
- Volunteers
- 404 people
- Sponsor
- BriaCell Therapeutics Corporation
Multiple Myeloma, Refractory Multiple Myeloma
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory…
- Conditions
- Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
- Trial name
- NCT07377435
- Testing
- DC/MM Fusion Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- David Avigan
Neuroblastoma Recurrent
Quadruple Immunotherapy for Neuroblastoma
This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating…
- Trial name
- NCT05754684
- Testing
- Natural killer cell, Dinutuximab beta, Interleukin-2
- Where
- Hong Kong
- Volunteers
- 29 people
- Sponsor
- Hong Kong Children's Hospital
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastoma (MB) looking at the feasibility and safety of adoptive cell therapy plus PD-1 blockade.
- Trial name
- MATCHPOINT (NCT06514898)
- Testing
- TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Neuroblastoma
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
The purpose of the study is to explore the combination of a bivalent vaccine, a sugar called beta-glucan (β-glucan), and a protein called granulocyte-macrophage colony stimulating factor (GM-CSF) as an effective treatment for…
- Trial name
- NCT04936529
- Testing
- β-glucan, GM-CSF, OPT-821
- Where
- United States
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Carcinoma
Testing the SurVaxM Vaccine for Lung Cancer Prevention
This phase II trial tests how well a survivin peptide vaccine called SurVaxM works in preventing lung cancer in high risk patients.
- Trial name
- NCT07169617
- Testing
- Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Gastrointestinal Cancer
OH2 Oncolytic Viral Therapy in Solid Tumors
This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft…
- Trial name
- NCT03866525
- Testing
- OH2 injection, with or without irinotecan or HX008
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Advanced Ovarian Cancer
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer
The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian…
- Trial name
- Cornerstone4 (NCT05794659)
- Testing
- AST-201, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Aston Sci. Inc.
Neuroblastoma Recurrent
A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
The study participant is being asked to take part in this research study because the participant has been diagnosed with neuroblastoma that did not fully respond to previous treatment (refractory), or it has returned after…
- Trial name
- NCT07085338
- Testing
- Temozolomide, Irinotecan, hu14.18K322A
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- St. Jude Children's Research Hospital
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma.
- Conditions
- Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
- Trial name
- NCT03126916
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 164 sites in United States, Canada and 1 more
- Volunteers
- 750 people
- Sponsor
- Children's Oncology Group
Oncology, NSCLC Stage IV
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer.
- Conditions
- Oncology, NSCLC Stage IV, NSCLC, Stage III
- Trial name
- LUNGVAC (NCT05344209)
- Testing
- UV1, Sagramostim, Anti-PD-1/PD-L1 treatment
- Where
- Norway
- Volunteers
- 138 people
- Sponsor
- Vestre Viken Hospital Trust
Soft Tissue Sarcoma (STS)
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
The primary objective of this clinical trial is to evaluate the efficacy and safety of spatially fractionated radiotherapy combined with the PraG strategy in the treatment of soft tissue sarcoma (STS).
- Trial name
- NCT07342322
- Testing
- Spatially Fractionated Radiation Therapy Combined with Toripalimab and Human Granulocyte-Macrophage Colony-Stimulating Factor for Injection
- Where
- China
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific…
- Conditions
- Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
- Trial name
- NCT05544968
- Testing
- anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Medical College of Wisconsin
Advanced Refractory Solid Tumors
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
This study is a single-arm, multi-center, prospective clinical study aimed at exploring the efficacy and safety of cetuximab β combined with PRaG regimen in rescuing patients with EGFR-positive advanced refractory solid tumors.
- Trial name
- NCT07327411
- Testing
- Hypofractionated radiotherapy, PD-L1 inhibitor, GM-CSF
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Metastatic Uveal Melanoma
Tebentafusp-tebn With LDT in Metastatic UM
This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A*0201 positive patients with metastatic uveal melanoma.
- Trial name
- NCT06626516
- Testing
- Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Thomas Jefferson University
Neuroblastoma
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy.
- Trial name
- NCT05489887
- Testing
- Naxitamab
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 93 people
- Sponsor
- Giselle Sholler
Neuroblastoma
GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.
This exploratory clinical study will evaluate the efficacy and feasibility of combining a GSL synthase inhibitor with a granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with advanced or metastatic…
- Trial name
- NCT07090538
- Testing
- Eliglustat
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Diffuse Large B-cell Lymphoma, Relapsed and Refractory
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory…
- Trial name
- NCT06651853
- Testing
- Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Pseudomyxoma Peritonei
Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei
Participants will receive vaccination with Pseudovax/GM-CSF in combination with PD-1 inhibitor tislelizumab over a period of up to two years.
- Trial name
- Pseudovax (NCT07341360)
- Testing
- Pseudovax, Molgramostim, Tislelizumab
- Where
- Norway
- Volunteers
- 10 people
- Sponsor
- Oslo University Hospital
Transplant-Related Hematologic Malignancy
GM-CSF With Post-Transplant Cyclophosphamide
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the…
- Trial name
- NCT04237623
- Testing
- Sargramostim, Control Arm
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northside Hospital, Inc.